| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.16 | 0.0006 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | Panobinostat | CTRPv2 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | 0.097 | 0.004 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |